Healthcare
June 22, 2020 / 1:19 PM / 13 days ago

BRIEF-Beigene And Springworks Announce Presentation Of Preclinical Data From Solid Tumors Treatment

1 Min Read

June 22 (Reuters) - Springworks Therapeutics Inc:

* BEIGENE AND SPRINGWORKS ANNOUNCE PRESENTATION OF PRECLINICAL DATA COMBINING RAF DIMER INHIBITOR LIFIRAFENIB WITH MEK INHIBITOR MIRDAMETINIB AND PROVIDE UPDATE ON ONGOING PHASE 1B/2 CLINICAL TRIAL

* SPRINGWORKS THERAPEUTICS - ONGOING PHASE 1B/2 CLINICAL TRIAL ON TRACK TO COMMENCE DOSE EXPANSION COHORTS IN KRAS MUTANT SOLID TUMORS BY 2020-END Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below